Association of Robust Anti-SARS-CoV-2 Trajectories among Communities with and without COVID-19 Infection

Abstract

Globally, 767 million people have been affected by SARS-CoV-2 infection and nearly a population of 6.94 million were deceased as per the World Health Organization (WHO) as of June 7, 2023. In India, the spreading of infections is now being restricted by the use of BBV-152 (CovaxinTM) and ChAdOx1-nCOV (CovishieldTM) vaccines. The present study comprises 327 candidates and Chemiluminescent microparticle immunoassay (CMIA) was used as a quantitative analytical tool to detect IgG and IgM antibodies. Out of 327 candidates, 177 (54.1%) were vaccinated and 150 (45.9%) were non-vaccinated. Among vaccinated and non-vaccinated candidates, 49 (27.7%%) and 44 (29.3%) had a history of infection, respectively; meanwhile, most of the study participants were immunized with CovishieldTM (n=145, 81.9%) and 18.1% (n=32) were immunized with CovaxinTM. There were insignificant differences observed among immunized as well as non-immunized study participants in considering median age, gender, age categories, IgM levels, or IgM seropositivity. Predictably, there was an important variation in IgG median values and IgG positivity noticed among the immunized and non-immunized categories as well as between populations with and without preceding infections. Our research is hence coherent with prospective requirements for booster shots to assist in controlling the rate of infections and fatality rates together throughout the pandemic conditions.

Keywords

• sars-cov-2
• chemiluminescent microparticle immunoassay
• igg antibody
• covaxin
• covishield
• vaccine
• covid-19